Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Novartis' antibody deals

Novartis' antibody deals

Year Company Deal
2007 MorphoSys (FSE:MOR) Expands a 2004 deal, getting access to future HuCAL technology upgrades and giving MOR an option to

Read the full 261 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE